 BioTelemetry NASDAQ:BEAT was downgraded by Zacks Investment Research from a buy rating to a hold rating in a report released on Monday, Zacks.com reports. According to Zacks, BioTelemetry, Inc. provides ambulatory outpatient management solutions for monitoring clinical information regarding an individuals health. It is focused on the diagnosis and monitoring of cardiac arrhythmias, or heart ... 